Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease.

Kim GHJ, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, Khanna D, Elashoff RM, Tseng CH, Roth MD, Goldin JG.

Arthritis Rheumatol. 2019 Aug 20. doi: 10.1002/art.41085. [Epub ahead of print]

PMID:
31430058
2.

Employing a glutathione-s-transferase-tag and hyaluronidase to control cytokine retention and release from a hyaluronic acid hydrogel matrix.

Harui A, Roth MD.

J Biomater Appl. 2019 Nov;34(5):631-639. doi: 10.1177/0885328219867974. Epub 2019 Aug 6. No abstract available.

PMID:
31387421
3.

Pulmonary effects of inhaled cannabis smoke.

Tashkin DP, Roth MD.

Am J Drug Alcohol Abuse. 2019 Jul 12:1-14. doi: 10.1080/00952990.2019.1627366. [Epub ahead of print]

PMID:
31298945
4.

Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.

Arthritis Rheumatol. 2019 Jun 24. doi: 10.1002/art.41020. [Epub ahead of print]

PMID:
31233287
5.

Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM.

J Rheumatol. 2019 Feb 15. pii: jrheum.180441. doi: 10.3899/jrheum.180441. [Epub ahead of print]

PMID:
30770517
6.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP.

Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.

7.

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups.

Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.

8.

A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers.

Kiertscher SM, Gangalum PR, Ibrahim G, Tashkin DP, Roth MD.

J Neuroimmune Pharmacol. 2018 Jun;13(2):219-229. doi: 10.1007/s11481-018-9776-7. Epub 2018 Jan 16.

9.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):644-652. doi: 10.1164/rccm.201709-1845OC. Epub 2017 Nov 3.

10.

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.

Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):439-444. doi: 10.1002/acr.23282. Epub 2018 Feb 9.

11.

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.

Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.

Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23.

12.

Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation.

Castaneda JT, Harui A, Roth MD.

J Neuroimmune Pharmacol. 2017 Sep;12(3):544-554. doi: 10.1007/s11481-017-9744-7. Epub 2017 Mar 31.

13.

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.

Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S.

Arthritis Res Ther. 2016 Dec 30;18(1):305. doi: 10.1186/s13075-016-1203-y.

14.

Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.

Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM.

Chest. 2017 Apr;151(4):813-820. doi: 10.1016/j.chest.2016.11.052. Epub 2016 Dec 22.

15.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

16.

Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.

Kim HJ, Tashkin DP, Gjertson DW, Brown MS, Kleerup E, Chong S, Belperio JA, Roth MD, Abtin F, Elashoff R, Tseng CH, Khanna D, Goldin JG.

Ann Rheum Dis. 2016 Jul;75(7):1367-71. doi: 10.1136/annrheumdis-2015-208929. Epub 2016 Jan 12.

PMID:
26757749
17.

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.

Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, Wells A, Furst DE, Clements PJ, Roth MD, Tashkin DP, Goldin J.

Arthritis Res Ther. 2015 Dec 23;17:372. doi: 10.1186/s13075-015-0872-2.

18.

Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model.

Roth MD, Harui A.

J Immunother Cancer. 2015 Apr 21;3:12. doi: 10.1186/s40425-015-0056-2. eCollection 2015.

19.

Exposure to Δ9-Tetrahydrocannabinol Impairs the Differentiation of Human Monocyte-derived Dendritic Cells and their Capacity for T cell Activation.

Roth MD, Castaneda JT, Kiertscher SM.

J Neuroimmune Pharmacol. 2015 Jun;10(2):333-43. doi: 10.1007/s11481-015-9587-z. Epub 2015 Jan 23.

20.

Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.

Tashkin DP, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, Elashoff R.

Ann Rheum Dis. 2016 Feb;75(2):374-81. doi: 10.1136/annrheumdis-2014-206076. Epub 2014 Dec 1.

PMID:
25452309
21.

Pleural effusions, eosinophilia and a positive interferon-γ release assay.

Howard-Anderson J, Canan T, Roth MD, Ha E.

Respiration. 2013;86(6):508-11. doi: 10.1159/000355096. Epub 2013 Nov 5. No abstract available.

22.

Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema.

D'Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, Wise RA, Sciurba FC, Scharf SM, Thankachen J, Islam M, Ghio AJ, Foronjy RF.

PLoS One. 2013;8(2):e56352. doi: 10.1371/journal.pone.0056352. Epub 2013 Feb 18.

23.

Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes.

Castaneda JT, Harui A, Kiertscher SM, Roth JD, Roth MD.

J Neuroimmune Pharmacol. 2013 Mar;8(1):323-32. doi: 10.1007/s11481-012-9430-8. Epub 2013 Jan 10.

24.

Lung cancer chemoprevention with celecoxib in former smokers.

Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D.

Cancer Prev Res (Phila). 2011 Jul;4(7):984-93. doi: 10.1158/1940-6207.CAPR-11-0078.

25.

Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.

Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin DP.

Arthritis Rheum. 2011 Oct;63(10):3078-85. doi: 10.1002/art.30467.

26.

Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.

Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM; Scleroderma Lung Study Research Group.

Arthritis Rheum. 2011 Sep;63(9):2797-808. doi: 10.1002/art.30438.

27.

Adverse events during the Scleroderma Lung Study.

Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE; Scleroderma Lung Study.

Am J Med. 2011 May;124(5):459-67. doi: 10.1016/j.amjmed.2010.12.009.

PMID:
21531236
28.

Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.

Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, Tashkin D, Roth MD, Elashoff R, Furst DE.

Arthritis Care Res (Hoboken). 2010 Dec;62(12):1772-8. doi: 10.1002/acr.20320.

29.

Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation.

Harui A, Kiertscher SM, Roth MD.

J Neuroimmune Pharmacol. 2011 Mar;6(1):148-57. doi: 10.1007/s11481-010-9223-x. Epub 2010 Jun 8.

30.

Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.

Morizono K, Ku A, Xie Y, Harui A, Kung SK, Roth MD, Lee B, Chen IS.

J Virol. 2010 Jul;84(14):6923-34. doi: 10.1128/JVI.00435-10. Epub 2010 May 19.

31.

Eosinophil and T cell markers predict functional decline in COPD patients.

D'Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, Sternberg D, Goldin JG, Louis TA, Mao JT, O'Connor GT, Ramsdell JW, Ries AL, Schluger NW, Sciurba FC, Skeans MA, Voelker H, Walter RE, Wendt CH, Weinmann GG, Wise RA, Foronjy RF.

Respir Res. 2009 Nov 19;10:113. doi: 10.1186/1465-9921-10-113.

32.

Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.

Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, Vasunilashorn S, Li G, Tashkin DP.

Chest. 2009 Nov;136(5):1333-1340. doi: 10.1378/chest.09-0108.

33.

Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers.

Kye SH, Tashkin DP, Roth MD, Adams B, Nie WX, Mao JT.

Contemp Clin Trials. 2009 Sep;30(5):464-72. doi: 10.1016/j.cct.2009.05.004. Epub 2009 Jun 7.

PMID:
19508900
34.

Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men.

Chao C, Jacobson LP, Jenkins FJ, Tashkin D, Martínez-Maza O, Roth MD, Ng L, Margolick JB, Chmiel JS, Zhang ZF, Detels R.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):149-56. doi: 10.1089/aid.2008.0196.

35.

Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma.

Chao C, Jacobson LP, Tashkin D, Martínez-Maza O, Roth MD, Margolick JB, Chmiel JS, Holloway MN, Zhang ZF, Detels R.

Cancer Causes Control. 2009 Jul;20(5):509-16. doi: 10.1007/s10552-008-9258-y. Epub 2008 Nov 15.

36.

High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease.

Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; Scleroderma Lung Study Research Group.

Chest. 2008 Aug;134(2):358-367. doi: 10.1378/chest.07-2444. Epub 2008 Jul 18.

PMID:
18641099
37.

Clarifying CB2 receptor-dependent and independent effects of THC on human lung epithelial cells.

Sarafian T, Montes C, Harui A, Beedanagari SR, Kiertscher S, Stripecke R, Hossepian D, Kitchen C, Kern R, Belperio J, Roth MD.

Toxicol Appl Pharmacol. 2008 Sep 15;231(3):282-90. doi: 10.1016/j.taap.2008.05.001. Epub 2008 May 9.

38.

Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men.

Chao C, Jacobson LP, Tashkin D, Martínez-Maza O, Roth MD, Margolick JB, Chmiel JS, Rinaldo C, Zhang ZF, Detels R.

Drug Alcohol Depend. 2008 Apr 1;94(1-3):165-71. doi: 10.1016/j.drugalcdep.2007.11.010. Epub 2008 Jan 3.

39.

Pharmacokinetics and metabolism of all-trans- and 13-cis-retinoic acid in pulmonary emphysema patients.

Muindi JR, Roth MD, Wise RA, Connett JE, O'Connor GT, Ramsdell JW, Schluger NW, Romkes M, Branch RA, Sciurba FC; FORTE Study Investigators.

J Clin Pharmacol. 2008 Jan;48(1):96-107.

PMID:
18094222
40.

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; Scleroderma Lung Study Research Group.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8. Epub 2007 Sep 27.

41.

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group.

Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. Epub 2007 Aug 23.

42.

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.

Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE; Scleroderma Lung Study Group.

Ann Rheum Dis. 2007 Dec;66(12):1641-7. Epub 2007 May 7.

43.

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group.

Arthritis Rheum. 2007 May;56(5):1676-84.

44.

Pharmacokinetics of a novel agent, R667, in patients with emphysema.

Chiu YY, Roth MD, Kolis S, Rogovitz D, Davies B.

Br J Clin Pharmacol. 2007 May;63(5):527-33. Epub 2007 Feb 23.

45.

Feasibility of retinoids for the treatment of emphysema study.

Roth MD, Connett JE, D'Armiento JM, Foronjy RF, Friedman PJ, Goldin JG, Louis TA, Mao JT, Muindi JR, O'Connor GT, Ramsdell JW, Ries AL, Scharf SM, Schluger NW, Sciurba FC, Skeans MA, Walter RE, Wendt CH, Wise RA; FORTE Study Investigators.

Chest. 2006 Nov;130(5):1334-45.

PMID:
17099008
46.

Cyclophosphamide versus placebo in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group.

N Engl J Med. 2006 Jun 22;354(25):2655-66.

47.

Centrifugation enhances integrin-mediated transduction of dendritic cells by conventional and RGD-modified adenoviral vectors.

Harui A, Roth MD, Sanghvi M, Vira D, Mizuguchi H, Basak SK.

J Immunol Methods. 2006 May 30;312(1-2):94-104. Epub 2006 Mar 31.

PMID:
16626731
48.

Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins.

Harui A, Roth MD, Vira D, Sanghvi M, Mizuguchi H, Basak SK.

J Leukoc Biol. 2006 Jun;79(6):1271-8. Epub 2006 Mar 30.

PMID:
16574766
49.

Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo.

Sarafian TA, Habib N, Oldham M, Seeram N, Lee RP, Lin L, Tashkin DP, Roth MD.

Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1202-9. Epub 2006 Jan 13.

50.

Celecoxib decreases Ki-67 proliferative index in active smokers.

Mao JT, Fishbein MC, Adams B, Roth MD, Goodglick L, Hong L, Burdick M, Strieter ER, Holmes C, Tashkin DP, Dubinett SM.

Clin Cancer Res. 2006 Jan 1;12(1):314-20.

Supplemental Content

Support Center